Dazodalibep’s Benefits Seen In 2nd Sjögren’s Patient Group
Investigational therapy dazodalibep significantly eased symptom burden in people with Sjögren’s syndrome who have moderate-to-severe symptoms, but minimal systemic disease activity, meeting the goal of Horizon Therapeutics‘ Phase 2 clinical trial. Horizon previously announced the trial also met its other main goal of reducing disease activity in…